BioCentury
ARTICLE | Clinical News

Ligand regulatory update

October 12, 1998 7:00 AM UTC

LGND’s NDS for its Panretin alitretinoin 0.1 percent 9-cis-retinoic acid gel was accepted for priority review in Canada to treat AIDS-related Kaposi’s sarcoma. ...